In vitro and in vivo immunomodulating properties of mesenchymal stem cells

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 12, Issue 1, 2018, Pages 59-68

  Chaudhary, Divya ^a   Trivedi, Raj N ^b   Kathuria, Ashima ^a   Goswami, Tapas K ^c   Khandia, Rekha ^d   Munjal, Ashok ^d  

^a MEERUT INSTITUTE OF ENGINEERING AND TECHNOLOGY   (India)

^b G B PANT UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (India)

^c INDIAN VETERINARY RESEARCH INSTITUTE   (India)

^d BARKATULLAH UNIVERSITY   (India)

Author keywords

Cytokines; Immunomodulation; Inflammation; Mesenchymal stem cells (MSCs); T cells; Therapeutic properties; Tregs

Indexed keywords

PROSTAGLANDIN E2; TRANSCRIPTION FACTOR FOXP3; NITRIC OXIDE;

ALLERGY; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CELL VIABILITY ASSAY; CHRONIC PERIODONTITIS; GENE EXPRESSION; HUMAN; HYPERTENSION; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; MESENCHYMAL STEM CELL; MULTIPLE SCLEROSIS; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; CELL DIFFERENTIATION; HYPERSENSITIVITY; MESENCHYMAL STEM CELL TRANSPLANTATION; PATENT; PHYSIOLOGY;

ANIMALS; CELL DIFFERENTIATION; HUMANS; HYPERSENSITIVITY; HYPERTENSION; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; NITRIC OXIDE; OSTEOARTHRITIS; PATENTS AS TOPIC;

EID: 85052079932     PISSN: 1872213X     EISSN: 22122710     Source Type: Journal    
DOI: 10.2174/1872213X12666180227105924     Document Type: Review

References (136)

1. Kim EJ, Kim N, Cho SG. The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation. Exp Mol Med 2013; 45: e2.
2. Chaudhary D, Goswami TK, Munjal, AK, Singh, M, Ram, GC. Immunomodulatory effect of allogenic bone marrow-derived mesenchymal stem cells on salmonella-derived flagellin. Vet Immunol Immunop 2012; 14(1): 22-8.
3. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-7.
4. Izadpanah R, Trygg C, Patel B, Kriedt C, Dufour J, Gimble JM, et al. Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. J Cell Biochem 2006; 99: 1285-97.
5. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng 2001; 7: 211-28.
6. + cells. Exp Hematol 2004; 32: 657-64.
7. Roubelakis MG, Pappa KI, Bitsika V, Zagoura D, Vlahou A, Pa-padaki HA, et al. Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: Comparison to bone marrow mesenchymal stem cells. Stem Cells Dev 2007; 16: 931-52.
8. Erices K, Kern S, Kluter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004; 22: 625-34.
9. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 2006; 36: 2566-73.
10. Siegel G, Schafer R, Dazzi F. The immunosuppressive properties of mesenchymal stem cells. Transplantation 2009; 87(Suppl 9): S45-9.
11. Yanez R, Lamana ML, Garcia-Castro J, Colmenero I, Ramirez M, Bueren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells Dev 2006; 24: 2582-91.
12. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Caz-zanti F, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-72
13. Burchell JT, Strickland DH, Stumbles PA. The role of dendritic cells and regulatory T cells in the regulation of allergic asthma. Pharmacol Ther 2010; 125: 1-10.
14. Yen BL, Chang CJ, Liu KJ, Chen YC, Hu HI, Bai CH et al. Brief report-human embryonic stem cell-derived mesenchymal progenitors possess strong immunosuppressive effects toward natural killer cells as well as T lymphocytes. Stem Cells 2009; 27: 451-6.
15. Dhama K, Chakraborty S, Mahima, Wani MY, Verma AK, Deb R, et al. Novel and emerging therapies safeguarding health of humans and their companion animals: A review. Pak. J. Biol. Sci. 2013; 16(3): 101-11.
16. Khandia R, Munjal A, Dhama K, Malik YS. Bacterial toxins: A hope towards angiogenic ailments. Curr Drug Metab 2017;18(10): 926-41.
17. Khandia R, Munjal A, Kumar A, Singh G, Karthik K, Dhama K. Cell penetrating peptides: Biomedical/therapeutic applications with emphasis as promising futuristic hope for treating cancer. Int J Pharmacol 2017; 13(7): 677-89.
18. Khandia R, Pattnaik B, Rajukumar K, Pateriya A, Bhatia S, Murugkar H, et al. Anti-proliferative role of recombinant lethal toxin of Bacillus anthracis on primary mammary ductal carcinoma cells revealing its therapeutic potential. Oncotarget 2017; 8(22): 35835-47.
19. Khandia R, Munjal A, Bangrey RS, Mehra R, Dhama K, Sharma NC. Evaluation of silver nanoparticle mediated reduction of neovascularisation (angiogenesis) in chicken model. Adv Anim Vet Sci 2015; 3(7): 372-6.
20. Prasad M, Lambe UP, Brar B, Shah I, Koushlesh Ranjan MJ, Rao R, et al. Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world. Biomed Pharmaco 2018; 97: 1521-37.
21. Iqbal HMN, Rodriguez AMV, Khandia R, Munjal A, Dhama K. Recent trends in nanotechnology-based drugs and formulations for targeted therapeutic delivery. Recent Pat Inflamm Allergy Drug Discov 2017; 10 (2): 86-93.
22. Khandia R, Vishwakarma P, Dwivedi A, Mehra R, Kujur A, Dhama K, et al. Evaluation of the modulatory effects of copper salts on the process of Angiogenesis (Neovascularization) with therapeutic perspectives. Adv Anim Vet Sci 2016; 4 (8), 405-10.
23. Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: An update. Cell Transplant 2016; 25(5): 829-48.
24. Samsonraj RM, Rai B, Sathiyanathan P, Puan KJ, Rötzschke O, Hui JH, et al. Establishing criteria for human mesenchymal stem cell potency. Stem Cells 2015; 33(6): 1878-91.
25. L Ramos T, Sánchez-Abarca LI, Muntión S, Preciado S, Puig N, López-Ruano G, et al. MSC surface markers (CD44, CD73, and CD90) can identify human MSC-derived extracellular vesicles by conventional flow cytometry. Cell Commun Signal 2016; 14: 2.
26. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8(4): 315-7.
27. Orsi G, Barbolini M, Ficarra G, Tazzioli G, Manni P, Petrachi T, et al. GD2 expression in breast cancer. Oncotarget 2017; 8(19): 31592-600.
28. Battula VL, Treml S, Abele H, Bühring HJ. Prospective isolation and characterization of mesenchymal stem cells from human placenta using a frizzled-9-specific monoclonal antibody. Differentiation 2008; 76: 326-36.
29. Samsonraj RM, Raghunath M, Nurcombe V, Hui JH, van Wijnen AJ, Cool SM. Concise Review: Multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med 2017; 6(12): 2173-85.
30. Lv FJ, Tuan RS, Cheung KM, Leung VY. Concise review: The surface markers and identity of human mesenchymal stem cells. Stem Cells 2014; 32(6): 1408-19.
31. Ferlin KM, Kaplan DS, Fisher JP. Separation of mesenchymal stem cells through a strategic centrifugation protocol. Tissue Eng Part C Methods 2016; 22(4): 348-59.
32. Boyette LB, Creasey OA, Guzik L, Lozito T, Tuan RS. Human bone marrow-derived mesenchymal stem cells display enhanced clonogenicity but impaired differentiation with hypoxic preconditioning. Stem Cells Transl Med. 2014; 3(2): 241-54.
33. Reissis Y, García-Gareta E, Korda M, Blunn GW, Hua J. The effect of temperature on the viability of human mesenchymal stem cells. Stem Cell Res Ther 2013; 4(6): 139.
34. Cselenyák A, Pankotai E, Horváth EM, Kiss L, Lacza Z. Mesenchymal stem cells rescue cardiomyoblasts from cell death in an in vitro ischemia model via direct cell-to-cell connections. BMC Cell Biol 2010; 11: 29.
35. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 2003; 171: 3426-34.
36. Di Nicola M, Carlo-Stella C, Magni M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002: 99: 3838-43.
37. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F. Bone Marrow mesenchymal stem cells inhibit the response of naïve and memory antigen specific T cells to their cognate peptide. Blood 2003; 101: 3722-9.
38. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytesor natural killer cells. Transplantation 2003; 76: 1208-13.
39. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R, et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005; 35: 1482-90.
40. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102: 3837-44.
41. Wang LT, Jiang SS, Ting CH, Hsu PJ, Chang CC, Sytwu HK, et al. Differentiation of MSCs from human iPSCs result in downregulation of c-Myc & DNA replication pathways with immunomodulation toward CD4 & CD8 cells. Stem Cells 2018. doi: 10.1002/stem.2795.
42. Fu QL, Chow YY, Sun SJ, Zeng QX, Li HB, Shi JB et al. Mesenchymal stem cells derived from human induced pluripotent stem cells modulate T-cell phenotypes in allergic rhinitis. Allergy 2012; 67: 1215-22.
43. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 2003; 75: 389-97.
44. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-22.
45. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibitlymphocytes proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005; 305: 33-41.
46. Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Pescatori M, and Stubbs AP, et al. Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clin Exp Immunol 2010; 162: 474-86.
47. Raicevic G, Najar M, Najimi M, El Taghdouini A, van Grunsven LA, Sokal E, et al. Influence of inflammation on the immunological profile of adult-derived human liver mesenchymal stromal cells and stellate cells. Cytotherapy 2015; 17: 174-85.
48. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103: 4619-21.
49. Loisel S, Dulong J, Ménard C, Renoud ML, Meziere N, Isabelle B, et al. Proteasomal indoleamine 2,3-dioxygenase degradation reduces the immunosuppressive potential of clinical grade-mesenchymal stromal cells undergoing replicative senescence. Stem Cells 2017; 35(5):1431-6. doi: 10.1002/stem.2580.
50. Plumas J, Chaperot L, Richard MJ, Molens JP, Bensa JC, Favrot MC. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005; 19: 1597-1604.
51. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Ger-doni E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106:1755-61.
52. Choi JJ, Yoo SA, Park SJ, Kang YJ, Kim WU, Oh IH, et al. Mesenchymal stem cells overexpressing interleukin-10 attenuate colla-gen-induced arthritis in mice. Clin Exp Immunol 2008; 153(2): 269-76.
53. Wang J, Ren H, Yuan X, Ma H, Shi X, Ding Y. Interleukin-10 secreted by mesenchymal stem cells attenuates acute liver failure through inhibiting pyroptosis. Hepatol Res 2018; 48(3): E194-202.
54. Lee HJ, Kim SN, Jeon MS, Yi T, Song SU. ICOSL expression in human bone marrow-derived mesenchymal stem cells promotes induction of regulatory T cells. Sci Rep 2017; 7: 44486.
55. Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regula-tory/suppressive phenotype. Haematologica 2005; 90: 516-25.
56. Domenis, R, Quaglia, S, Cifù, A, C Pistis, Fabris M, Moretti M, et al. The immunomodulatory properties of adipose mesenchymal stem cell-derived exosomes are induced by inflammatory cytokines. The FASEB Journal 2017; 31(Suppl 1): 981-5.
57. Munir H, Ward LSC, Sheriff L, Kemble S, Nayar S, Barone F, et al. Adipogenic differentiation of mesenchymal stem cells alters their immunomodulatory properties in a tissue specific manner. Stem Cells 2017; 35(6):1636-46.
58. Gharibi T, Ahmadi M, Seyfizadeh N, Jadidi-Niaragh F, Yousefi M. Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis. Cell Immunol 2015; 293(2): 113-21.
59. Dalemans, W., Lombardo, E. Adipose-derived mesenchymal stem cells for intralymphatic administration in autoimmune and inflammatory diseases. WO2012095743 (2012).
60. Nolta, J.A., Olson, S., Wirthlin, L. Mesenchymal stem cells producing inhibitory RNA for disease modification. US20160263160 (2016).
61. Günther, C., Sabine Geiger-Schredelseker, S., Hermann, F., Huss, R., Forster, D.L. Genetically modified mesenchymal stem cells expressing alpha-1 antitrypsin (AAT). WO2016110565 (2016).
62. Mcintosh, K.R., Mosca, J.D., Klyushnenkova, E.N. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation. WO1999047163 (1999).
63. Frank, M.H. ABCB5 positive mesenchymal stem cells as immunomodulators. US8455245 (2013).
64. Caplan, A.I., Haynesworth, S.E. Human mesenchymal stem cells. US5486359 (1996).
65. Munoz, C.J.R., Diaz, T.J.M., Herenci, B.C., Rodriguez, O.M.E., Montes, D.G.A.R., Martinez-Moreno, J.M., et al. Improved differentiation of mesenchymal stem cells into osteoblasts. EP2899266 (2015).
66. Kadouri, A., Bar-Ilan, A., Melamed, E., Offen, D., Sadan, O., Ba-hat-Stromza, M. Mesenchymal stem cells for the treatment of CNS diseases. US9474787 (2016).
67. Günther, C., Theoharis, S., Hermann, F., Ralf Huss, R. Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells. WO2016026854 (2016).
68. Caplan, A.I., Bonfield, T.L. Mesenchymal stem cell compositions for the treatment of microbial infections. US20140134140 (2014).
69. Nolta, J.A., Olson S., Wirthlin L. Mesenchymal stem cells producing inhibitory RNA for disease modification. US20120114618 (2012).
70. Gothelf, Y., Levy, Y., Burshtein, A. Methods of generating mesenchymal stem cells which secrete neurotrophic factors. WO2014024183 (2014).
71. Arzi, B., Borjesson, D.L., Verstraete, F.J.M. Mesenchymal stem cells for oral inflammation treatment. US20160199414 (2016).
72. Weiss, M., Grumet, M.H. Encapsulated stem cells for the treatment of inflammatory disease. WO2016086020 (2016).
73. Bartholomew, A., Lee, S., Szilagyi, E. Activated mesenchymal stem cells for wound healing and impaired tissue regeneration. US9011840 (2015).
74. Camussi, G., Bruno, S., Bussolati, B. An isolated multipotent mesenchymal stem cell from human adult glomeruli (hGL-MSC), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney. WO2010052192 (2010).
75. Lee, J.J. Stem cell carrier and method for bone regeneration with 3D customized CAD/CAM using the carrier. EP3034102 (2016).
76. Gupta P.K., House A.C., Das A.K., Majumdar A.S., Raj S.S., Ba-lasubramanian S., Rengasamy M. Management of osteoarthritis us- ing pooled allogeneic mesenchymal stem cells. WO2015022670 (2015).
77. Hung S.C. Hypoxia-cultured mesenchymal stem cells for treating atherosclerotic lesions. US20160113968 (2016).
78. Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D, Dazzi F. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: Impact on in vivo tumor growth. Leukemia 2006; 21: 304-10.
79. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228-34.
80. Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: Pathological and therapeutic implications. Nat Immunol 2014; 15:1009-16.
81. Edwards TM, Rickard NS. New perspectives on the mechanisms through which nitric oxide may affect learning and memory processes. Neurosci Biobehav Rev 2007; 31: 413-25.
82. Murad, F. Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 2006; 355: 2003-11.
83. Niedbala W, Cai B, Liew FY. Role of nitric oxide in the regulation of T cell functions. Ann Rheum Dis 2006; 65(Suppl 3): 337-40.
84. Hoffman RA, Mahidhara RS, Wolf-Johnston AS, Lu L, Thomson AW, Simmons, RL. Differential modulation of CD4 and CD8 T-cell proliferation by induction of nitric oxide synthesis in antigen presenting cells. Transplantation 2002; 74: 836-45.
85. Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, et al. Mesenchymal stem cells and immunomodulation: Current status and future prospects. Cell Death Dis 2016; 7: e2062.
86. Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, et al. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004; 104: 3581-7.
87. Wojakowski W, Tendera M. Mobilization of bone marrow-derived progenitor cells in acute coronary syndromes. Folia Histochem Cy-tobiol 2005; 43: 229-32.
88. Chamberlain G, Fox J, Ashton B. and Middleton J. Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features and potential for homing. Stem Cells 2007; 25: 2739-49.
89. Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Rev 2006; 20: 161-71.
90. Schenk S, Mal N, Finan A, Zhang M, Kiedrowski M, Popovic Z, et al. MCP-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 2007; 25: 245-51.
91. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-50.
92. Nejad-Moghaddam A, Ajdary S, Tahmasbpour E, Rad FR, Panahi Yand Ghanei M. Immunomodulatory properties of mesenchymal stem cells can mitigate oxidative stress and inflammation process in human mustard lung. Biochem Genet 2016; 54(6): 769-83.
93. Djouad F, Fritz V, Apparailly F, Louis-Plence P, Bony C, Sany J, et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 2005; 52: 1595-603.
94. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-41.
95. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA. In-trapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007; 179: 1855-63.
96. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42-8.
97. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EGA, Wil-lemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006; 108: 2114-20.
98. Sudres M, Norol F, Trenado A, Gregoire S, Charlotte F, Levacher B, et al. Bone marrow mesenchymal stem cells suppress lympho-cyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 2006; 176: 7761-7.
99. Pistoia V, Raffaghello L. Mesenchymal stromal cells and autoimmunity. Int Immunol 2017; 29(2): 49-58.
100. Zhang J, Li Y, Chen J, Cui Y, Lu M, Elias SB, et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol 2005; 195: 16-26.
101. Hynes K, Bright R, Proudman S, Haynes D, Gronthos S, Bartold M. Immunomodulatory properties of mesenchymal stem cell in experimental arthritis in rat and mouse models: A systematic review. Semin Arthritis Rheum 2016; 46(1): 1-19.
102. Abd Elhalem SS, Haggag NZ, El-Shinnawy NA. Bone marrow mesenchymal stem cells suppress IL9 in adjuvant-induced arthritis. Autoimmunity 2018; 51(1): 25-34.
103. Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Amelioration of acute renal failure by stem cell therapy-paracrine secretion versus trans-differentiation into resident cells. J Am Soc Nephrol 2005; 16(5): 1153-63.
104. Kunter U, Rong S, Djuric Z, Boor P, Müller-Newen G, Yu D, et al. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 2006; 17: 2202-12.
105. Studeny M, Marini FC, Champlin, RE, Zompetta C, Fidler IJ, An-dreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002; 62: 3603-8.
106. Sundin M, Barrett AJ, Ringdén O, Uzunel M, Lönnies H, Dackland AL, et al. HSCT recipients have specific tolerance to MSC but not to the MSC donor. J Immunother 2009; 32(7): 755-64.
107. Moll G, Jitschin R, von Bahr L, Rasmusson-Duprez I, Sundberg B, Lönnies L, et al. Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses. PLOS One 2011; 6(7): e21703.
108. Moll G, Rasmusson-Duprez I, von Bahr L, Connolly-Andersen AM, Elgue G, Funke L, et al. Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells 2012; 30(7): 1565-74.
109. Rafei M, Birman E, Forner K, Galipeau J. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther. 2009; 17(10): 1799-1803. doi: 10.1038/mt.2009.157.
110. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2(2): 141-50.
111. Jiang H, Zhang Y, Tian K, Wang B, Han S. Amelioration of experimental autoimmune encephalomyelitis through transplantation of placental derived mesenchymal stem cells. Sci Rep 2017; 7: 41837.
112. Itakura S, Asari S, Rawson J, Ito T, Todorov I, Liu CP, et al. Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat. Am J Transplant 2007; 7: 336-46.
113. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, et al. Mesenchymal stem cells for treatment of therapy resistant graft versus-host disease. Transplantation 2006; 81: 1390-7.
114. Abumaree MH, Abomaray FM, Alshabibi MA, AlAskar AS, Kali-onis B. Immunomodulatory properties of human placental mesenchymal stem/stromal cells. Placenta 2017; 59: 87-95.
115. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004; 36(4): 568-84.
116. Diekman BO, Rowland CR, Lennon DP, Caplan AI, Guilak F. Chondrogenesis of adult stem cells from adipose tissue and bone marrow: Induction by growth factors and cartilage-derived matrix. Tissue Eng Part A 2010; 16(2): 523-33.
117. Yubo M, Yanyan L, Li L, Tao S, Bo L, Lin C. Clinical efficacy and safety of mesenchymal stem cell transplantation for osteoarthritis treatment: A meta-analysis. PLOS One 2017; 12(4): e0175449.
118. Freitag J, Bates D, Boyd R, Shah K, Barnard A, Huguenin L, et al. Mesenchymal stem cell therapy in the treatment of osteoarthritis: Reparative pathways, safety and efficacy-a review. BMC Muscu-loskelet Disord. 2016; 17: 230.
119. Jo CH, Lee YG, Shin WH, Kim H, Chai JW, Jeong EC, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: A proof-of-concept clinical trial. Stem Cells 2014; 32(5):1254-66.
120. Liang J, Zhang H, Wang D, Feng X, Wang H, Hua B, et al. Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease Gut 2012; 61: 468-9.
121. Abdel Salam AG, Ata HM, Salman TM, Rashed LA, Sabry D, Schaalan MF. Potential therapeutic utility of mesenchymal stem cells in inflammatory bowel disease in mice. Int Immunopharmacol 2014; 22(2): 515-21.
122. Tassi SA, Sergio NZ, Misawa MYO, Villar CC. Efficacy of stem cells on periodontal regeneration: Systematic review of pre-clinical studies. J Periodontal Res 2017; 52(5): 793-812.
123. Myers WC, Fountain SB. Dental pulp regeneration aided by blood and blood substitutes after experimentally induced periapical infection. Oral Surg Oral Med Oral Pathol 1974; 37(3): 441-50.
124. Gronthos S, Mankani M, Brahim J, Gehron Robey P, Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci USA 2000; 97(25): 13625-30.
125. Duan X, Tu Q, Zhang J, Ye J, Sommer C, Mostoslavsky G, et al. Application of induced pluripotent stem (iPS) cells in periodontal tissue regeneration. J Cell Physiol 2011; 226(1): 150-7.
126. Yoshida K, Sato J, Takai R, Uehara O, Kurashige Y, Nishimura M, et al. Differentiation of mouse iPS cells into ameloblast-like cells in cultures using medium conditioned by epithelial cell rests of Malassez and gelatin-coated dishes. Med Mol Morphol 2015; 48(3): 138-45.
127. Lightner AL. Stem cell therapy for inflammatory bowel disease. Clin Transl Gastroenterol (2017); 8: e82.
128. Khandia R, Munjal AK, Iqbal HMN, Dhama K. Heat shock proteins: therapeutic perspectives in inflammatory disorders. Recent Pat Inflamm Allergy Drug Discov 2017; 10(2): 94-104.
129. Frodermann V, van Duijn J, van Pel M, van Santbrink PJ, Bot I, Kuiper J, et al. Mesenchymal Stem Cells Reduce Murine Atherosclerosis Development. Sci Rep 2015; 5: 15559.
130. Li F, Guo X, Chen SY. Function and therapeutic potential of mesenchymal stem cells in atherosclerosis. Front Cardiovasc Med. 2017; 4: 32.
131. Sun YQ, Deng MX, He J, Zeng QX, Wen W, Wong DS, et al. Human pluripotent stem cell-derived mesenchymal stem cells prevent allergic airway inflammation in mice. Stem Cells 2012; 30(12): 2692-9.
132. Ren NN, Chen HJ, Chen QL, Eileen J, An YG, Lin Y. Effects of human mesenchymal stem cells on airway inflammation in allergic asthma mice and the underlying mechanism. Zhonghua Yi Xue Za Zhi. 2017; 97(34): 2697-702.
133. Kang SY, Park DE, Song WJ, Bae BR, Lee JW, Sohn KH, et al. Immunologic regulatory effects of human umbilical cord blood-derived mesenchymal stem cells in a murine ovalbumin asthma model. Clin Exp Allergy 2017; 47(7): 937-45.
134. Nejad-Moghaddam A, Ajdary S, Tahmasbpour E, Rad FR, Panahi Y, Ghanei M. Immunomodulatory properties of mesenchymal stem cells can mitigate oxidative stress and inflammation process in human mustard lung. Biochem Genet. 2016; 54: 769.
135. Gnecchi M, Zhang Z, Ni A, Dzau V. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008; 103(11): 1204-19.
136. Oliveira-Sales EB, Maquigussa E, Semedo P, Pereira LG, Ferreira VM, Câmara NO, et al. Mesenchymal Stem Cells (MSC) prevented the progression of renovascular hypertension, improved renal function and architecture. PLOS One. 2013; 8(11): e78464.